Join UroGen Pharma for a virtual investor event featuring key opinion leaders (KOLs) Karim Chamie, MD (UCLA Health), Aaron Berger, MD (Associated Urological Specialists, Chicago), and Jennifer Linehan, MD (Saint John’s Cancer Institute at Providence, Santa Monica), who will join UroGen management to discuss the significant unmet need and current treatment landscape for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The event will include an overview of UroGen’s ZUSDURI™, the first and only FDA-approved medicine for adults with recurrent LG-IR-NMIBC. The KOL panel will share real-world clinical perspectives on the use of ZUSDURI, including patient selection, integration into practice, and observed outcomes, followed by a patient interview.

A live question and answer session will follow the formal presentations.